FDA Approves Lipfendra as First Oral PCSK9 Inhibitor for High Cholesterol Management
On July 17, 2026, the U.S. Food and Drug Administration (FDA) granted approval for Lipfendra (enlicitide), the first oral inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9). This medication is intended as an adjunct to diet and exercise for reducing low-density lipoprotein cholesterol (LDL-C), commonly referred to as "bad" cholesterol, in adults suffering from hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH). Previously, PCSK9 inhibitors were only available as injectable therapies, but Lipfendra offers a once-daily oral tablet option, expanding treatment possibilities for individuals who need further LDL-C reduction despite current therapies. The approval reflects ongoing advancements in managing chronic cardiovascular diseases. Dr. Michael Davis, Acting Director of the FDA’s Center for Drug Evaluation and Research, emphasized the significance of this approval, stating that cardiovascular disease remains the leading cause of death in the U.S., with elevated LDL cholesterol being a critical modifiable risk factor. He noted that this new option enhances treatment for adults with hypercholesterolemia and aligns with the FDA's commitment to improving patient access to effective therapies. Hypercholesterolemia is characterized by excessive LDL-C in the bloodstream, which can lead to plaque formation in arteries, increasing the risk of heart attack or stroke. Symptoms are often absent, making routine blood testing crucial for detection. Contributing factors to elevated cholesterol levels include diet, lack of physical activity, excess body weight, and genetic predispositions. Various medications exist to lower LDL-C, including statins, ezetimibe, and injectable PCSK9 inhibitors, with Lipfendra being the first oral option. The efficacy and safety of Lipfendra were assessed in two randomized, double-blind, placebo-controlled trials involving 3,207 adults with hypercholesterolemia, including those with and without HeFH, who were on maximally tolerated statin therapy. The primary endpoint was the percent change in LDL-C from baseline to Week 24 compared to placebo. In the first trial, which included adults with established atherosclerotic cardiovascular disease (ASCVD) or those at high risk for ASCVD, participants had a mean baseline LDL-C of 96 mg/dL. Results showed a 56% average reduction in LDL-C at Week 24 for those treated with Lipfendra compared to placebo. The second trial, which focused on adults with HeFH, had a mean baseline LDL-C of 119 mg/dL, with Lipfendra treatment resulting in a 59% average reduction at Week 24. Adverse reactions were similar between the Lipfendra and placebo groups, with diarrhea and dizziness reported more frequently among Lipfendra users in the second trial. Discontinuation rates due to adverse reactions were comparable across both groups. Lipfendra received Priority Review and was evaluated under the Commissioner’s National Priority Voucher pilot program, aimed at expediting the review of therapies addressing national public health priorities. The approval was granted to Merck Sharp & Dohme LLC, and the FDA continues its role in safeguarding public health by ensuring the safety and effectiveness of medications and other health-related products.




